Latest news
AstraZeneca’s Datroway wins EU approval as first TROP2-directed therapy for breast cancer - Indian Pharma PostIndian Pharma Post · Wed, 05 Aug 2026 14:18:22 GMTAstraZeneca's and Daiichi's Datroway wins EU breast cancer approval - London South EastLondon South East · Fri, 31 Jul 2026 08:49:00 GMTAstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer - Seeking AlphaSeeking Alpha · Fri, 31 Jul 2026 07:00:00 GMTDatroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy - Business WireBusiness Wire · Fri, 31 Jul 2026 07:00:00 GMTDatroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy - AstraZenecaAstraZeneca · Fri, 31 Jul 2026 02:00:00 GMT